الفهرس 
TitleOnly 14 pages are availabe for public view
 |  | from | 103 |  |  |
| | | from | 103 | | |
Abstract
Background: Triple negative breast cancer is defined by the absence of ER expression, PR expression and HER2 amplification (28). No targeted treatment is available for TNBC and chemotherapy remains the best therapeutic option. However, in the case of recurrence or chemo resistance, therapeutic options are very limited (29).
TNBC presents a high rate of proliferation and is highly aggressive (32-35). TNBC have lower survival rate and high rate of long-distance metastasis after treatment (33). As the complexity of this disease is being simplified over time new targets are also being discovered for the treatment of this disease (131).
Therefore, there is still need for new biomarkers, proteins playing important roles in the process of malignant transformation of the cells, which would serve for targeted treatment (131). Transgelin was proposed as new potential cancer biomarkers. Altered expression of Transgelin has been described in a wide range of cancers, often with contradictory results (95).
Aim: The present work aims at study of Transgelin expression across molecular subtypes of breast cancer, with emphasis on comparing Transgelin expression in triple negative and non triple negative tumors, to identify if Trangelin can be used as a molecular targeted protein for breast cancer patients in the future.
Materials and methods: the immunohistochemical expression of Transgelin was studied in 60 cases of invasive breast carcinoma (NST) with different molecular subtypes. Special interest was given to TNBC.
Results: Transgelin expression was positive in 23 cases and negative in 37 cases. There was a statistically significant difference between (TGLN +) and (TGLN-) cases as regards tumor size , tumor grade , lymphovascular invasion, lymph node status , ER status, PR status , Ki67 proliferation index and molecular subtype while there was no statistically significant difference between (TGLN+) and (TGLN-) as regards age and Her2 receptor status.
Conclusion: Transgelin is an aggressive breast cancer marker differentially expressed among the molecular breast cancer subtypes with high expression in triple negative breast cancer. Transgelin may provide a potential target for future treatment of triple negative breast cancer.